Drugs / Paclitaxel
Drug research

Paclitaxel

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Nov-Onxol, Onxol, Navaplus, Taxol; Taxol; Weekly Paclitaxel

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)NCT05002127ALX Oncology Inc.Phase 2, Phase 3Active not recruiting2024-05-24Actual
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 MutationsNCT01953926PBYIPhase 2Terminated2023-01-02Actual
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)NCT07465757PBYIPhase 2Recruiting2028-03-31Estimated
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLCNCT06246110Eikon TherapeuticsPhase 2Active not recruiting2026-12Estimated
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerNCT07007559ALX Oncology Inc.Phase 2Recruiting2027-12Estimated
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 StudyNCT04215146Oncolytics BiotechPhase 2Active not recruiting2022-08-01Actual
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerNCT06072781VSTMPhase 3Recruiting2028-10-15Estimated
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerNCT04736173RCUSPhase 2Active not recruiting2027-05Estimated
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerNCT07102381Jazz PharmaceuticalsPhase 2Recruiting2028-01-01Estimated
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)NCT05506943Compass TherapeuticsPhase 2, Phase 3Active not recruiting2027-08-31Estimated
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal CancerNCT06915025ImunonPhase 3Recruiting2032-10-31Estimated
Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)NCT03940196NVCRPhase 3Completed2023-05-18Actual
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsNCT03645928IOVAPhase 2Terminated2026-02-20Actual
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1NCT05870748STROPhase 2, Phase 3Terminated2025-08-26Actual
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial CancerNCT06463028Faeth TherapeuticsPhase 2Recruiting2028-09Estimated

Regulatory dates and decisions

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.